Dhingra Ankur 4
4 · Summit Therapeutics Inc. · Filed Jun 2, 2022
Insider Transaction Report
Form 4
Dhingra Ankur
Chief Financial Officer
Transactions
- Award
Stock Option (right to buy)
2022-05-31+600,000→ 600,000 totalExercise: $1.33Exp: 2032-05-31→ Common Stock (600,000 underlying)
Footnotes (2)
- [F1]The option was granted on May 31, 2022. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on May 31, 2023 (the one-year anniversary of the grant date).
- [F2]Not applicable.